Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan
暂无分享,去创建一个
Thomas Y. Hsueh | Chao-yuan Huang | Wen-Jeng Wu | Tsu-Ming Chien | Ching-Chia Li | Wei-Yu Lin | Wei‐Ming Li | I. Chen | Hsiang-Ying Lee | H. Yeh | C. Lo | Jen-Shu Tseng | Yu-Khun Lee | Chung-You Tsai | Yung-Tai Chen | B. Chiang | Chia-Chang Wu | H. Weng | Y. Tsai | Jian-Hua Hong | Chi-Ping Huang | Chao‐Hsiang Chang | T. Tai | H. Ke | Lian Yu | Zai-Lin Sheu
[1] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.
[2] S. Boorjian,et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] K. Bensalah,et al. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. , 2019, Urologic oncology.
[4] B. Taylor,et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma , 2018, Clinical Cancer Research.
[5] N. Xu,et al. Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma , 2018, Tumori.
[6] Y. Osman,et al. Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: A review of 305 patients. , 2018, Turkish journal of urology.
[7] T. Powles,et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[8] Chang-li Wu,et al. Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases , 2017, Medicine.
[9] Choung-Soo Kim,et al. Impact of Tumor Location on Local Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma: Implications for Adjuvant Radiotherapy , 2017, Clinical genitourinary cancer.
[10] M. Babjuk,et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) , 2017, World Journal of Urology.
[11] Sheau-Fang Yang,et al. Prognostic Significance of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma is Influenced by Tumor Location , 2015, Annals of Surgical Oncology.
[12] B. Milojevic,et al. Urothelial carcinoma: Recurrence and risk factors. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[13] Chao-yuan Huang,et al. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma , 2015, Diabetes/metabolism research and reviews.
[14] Jonathan Izawa,et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. , 2014, Urologic oncology.
[15] C. Tulić,et al. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. , 2013, Urologic oncology.
[16] Tianyuan Xu,et al. Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria , 2013, World Journal of Urology.
[17] S. Shariat,et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy , 2012, BJU international.
[18] F. Saint,et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. , 2011, European urology.
[19] J. Coleman,et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. , 2010, European urology.
[20] S. Shariat,et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. , 2010, European urology.
[21] K. Bensalah,et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. , 2010, European urology.
[22] F. Montorsi,et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. , 2009, The Journal of urology.
[23] Y. Lotan,et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.
[24] K. Bensalah,et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Rehak,et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location , 2006, BJU international.
[26] H. Ozen,et al. Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. , 2006, The Journal of urology.
[27] Liang Cheng,et al. Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis , 2005, Clinical Cancer Research.
[28] R. Takahashi,et al. Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.
[29] Matthew P. Goetz,et al. NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .
[30] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[31] H. Miyake,et al. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. , 2008, Urology.
[32] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.